Prominin-1 (PROM1) is known to be upregulated in hepatocytic progenitor cells (HPCs) and cholangiocytes of fibrotic livers. To understand the function of upregulated PROM1 during liver fibrosis, we analyzed liver fibrosis from global and liverspecific Prom1 knockout mice and investigated the molecular mechanism of how Prom1 protects the liver against liver fibrosis.
Introduction
Liver fibrosis results from the accumulation of collagen scar tissue following chronic liver injuries caused by nonalcoholic steatohepatitis (NASH), alcohol, hepatitis viral infection and autoimmune hepatitis 1, 2 . Chronic liver fibrosis progresses into hepatocellular carcinoma and cirrhosis with characteristics of ascites, jaundice (yellow skin), hepatic hypertension and hepatic encephalopathy if the cause is not eliminated 3 . Liver fibrosis is initiated by damaged hepatocytes and infiltrated macrophages, which secrete profibrogenic cytokines such as transforming growth factor-β (TGFβ), platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), sonic hedgehog (SHH) and WNT4. Hepatic stellate cells (HSCs) residing between hepatocytes and endothelial cells are proliferated and activated by these profibrogenic cytokines to produce extracellular matrix (ECM) components such as collagen and fibronectin 4-6 .
TGFβ binds to its type II receptor (TβRII), recruiting and phosphorylating its type I receptor (TβRI) in HSCs. Activated TβRI induces the phosphorylation of SMAD2 and SMAD3, and the activated SMAD2/3 then binds to SMAD4. The SMAD2/3-SMAD4 complex enters the nucleus and acts as a transcription factor to upregulate the genes encoding type I collagens (COL1A1 and COL1A2), tissue inhibitors of matrix metalloproteases (TIMPs) and α-smooth muscle actin (ACTA2) 7, 8 . The activated SMAD2/3-SMAD4 complex also upregulates SMAD7, a negative feedback inhibitor of TGFβ signaling. SMAD7 binds to TβRI and induces the ubiquitination and degradation of TβRI by recruiting SMAD ubiquitination regulatory factors 1 and 2 (SMURF1 and 2), thereby preventing TGFβ-induced phosphorylation and activation of SMAD2/3 [9] [10] [11] . SMAD7 also prevents the phosphorylation of SMAD3 or formation of the SMAD2/3-SMAD4 complex without TβRI ubiquitination 12, 13 . TGFβ plays important roles in hepatocytes during liver fibrosis 7, 8 . For example, hepatocyte-specific Tgfbr2 deletion or Smad7 overexpression prevents liver fibrosis development via NASH, bile duct ligation (BDL) and carbon tetrachloride (CCl 4 ) [14] [15] [16] .
Transdifferentiation of primary-cultured hepatocytes into myofibrils is also prevented by adenoviral overexpression of Smad7 14 .
Prominin-1 (PROM1), also called CD133, is a pentaspan transmembrane glycoprotein expressed in hematopoietic, epithelial and intestinal progenitor cells 17, 18 . PROM1 is expressed in rat HSCs and has been used as a cell-surface marker to isolate hepatic progenitor cells (HPCs) 19 . High expression levels of PROM1 are also observed in HPCs and cholangiocytes after liver injuries, such as those resulting from rhesus rotavirus (RRV)induced biliary atresia (BA) and BDL 20, 21 . Because Prom1 deficiency was shown to protect against RRV-induced liver fibrosis in mice, upregulated Prom1 in HPCs might be necessary to promote biliary fibrosis 22 .
In addition to HPCs and cholangiocytes, we found PROM1 to be expressed in hepatocyte plasma membranes of both healthy and fibrotic livers. We also demonstrated that PROM1 deficiency aggravated BDL-and CCl 4 -induced liver fibrosis and enhanced TGFβ signaling by reducing SMAD7 protein expression in hepatocytes. Because PROM1 interfered To generate different mouse fibrosis models, CCl 4 and BDL treatment were performed. Toxicant-induced models were generated by subcutaneous injections with either CCl 4 (1 ml/kg body weight) in corn oil (1:3 dilution), as a control, in six-week old male WT and KO C57BL/6 mice every third day for 6 weeks. The mice were killed 2 days after the final CCl 4 injection. For the BDL model, the mice were randomly divided into two groups. Animals that underwent BDL and sham operated animals were used as healthy controls. Briefly, mice were anesthetized using isoflurane. The extra-hepatic bile duct was isolated and doubly ligated.
The peritoneal cavity was filled with saline and the incisions were closed. Mouse body weight were measured daily. Seven days after the surgery, BDL and sham control animals were sacrificed.
Serum biochemistry
Serum ALT, AST and total bilirubin levels were analyzed using spectra-iMAX (Molecular Devices) and commercial kits from Biovision (San Francisco, USA). Serum levels were analyzed using commercial kits according to the manufacturer instructions.
Immunohistochemistry
Freshly frozen tissues post-fixed in 4% paraformaldehyde were subjected to immunohistochemistry analysis. Tissue sections were immunostained with antibodies against prominin-1 (eBioscience or Milteny Biotec), CK19, α SMA, Smad7, p-Smad2/3, Smad 2/3 and Vimentin. Briefly, the sections were pretreated with 2.5% horse serum for 20 min to block nonspecific antibody binding and then incubated with the antibodies of interest for overnight at 4°C. The slides were then treated with a FITC-or rhodamine-conjugated secondary antibody. After mounting with Permount solution, the samples were imaged on an LSM 800 META confocal microscope (Carl Zeiss, Thornwood, NY).
Preparation of mouse primary hepatocytes
Primary hepatocytes were isolated from 8-week-old C57BL/6 male mice as previously described. Briefly, mice were anesthetized with avertin (intraperitoneal injection of 250 mg/kg body weight), and livers were perfused with a pre-perfusion buffer (140 mM NaCl, 6 mM KCl, 10 mM HEPES, and 0.08 mg/mL EGTA, pH 7.4) at a rate of 7 mL/min for 5 min, followed by a continuous perfusion with a collagenase-containing buffer (66.7 mM NaCl, 6.7 mM KCl, 5 mM HEPES, 0.48 mM CaCl 2 , and 3 g/mL collagenase type IV, pH 7.4) for 8 min. Viable hepatocytes were harvested and purified with a Percoll cushion. Then, hepatocytes were resuspended in complete growth medium (199 medium containing 10% FBS, 23 mM HEPES and 10 nM dexamethasone) and seeded on collagen-coated plates at a density of 300,000 cells/ml. After a 4-h attachment period, the medium was replaced with complete growth medium before being used in any experiments and were changed daily.
Immunofluorescence staining
Livers and cells were fixed in 4% paraformaldehyde, and staining was performed as described previously. Signals were detected by secondary antibodies conjugated to either with anti-mouse, anti-rat rhodamine, or anti-rabbit antibodies. Fluorescence images were acquired on an LSM800 confocal microscope controlled by ZEN software (Carl Zeiss, Thornwood, NY). Bright-field images were acquired using a transmitted light microscope (Leica microsystems AG, Heerbrugg, Switzerland) and the Leica application system.
Western blotting analysis
Immunblot analyses were performed as previously described. Briefly, cells were harvested with lysis buffer (25 mM HEPES, 150 mM NaCl, 1% NP-40, 10 mM MgCl2, and 1 mM EDTA, pH 7.5) on ice for 20 min. The lysates were centrifuged at 10,000 g for 10 min to obtain supernatants. Proteins were separated by SDS-polyacrylamide gel electrophoresis, and the immobilized proteins were immunoblotted with the antibodies of interest. Table 2 shows the sequences of the primers used for qPCR.
Statistical analysis
Statistical values are presents as the mean ± S.E.M. A two-t-test was used to compare groups. *P<0.05, ** P <0.01, *** P <0.001.
Results

PROM1 is expressed in hepatocytes and CK19-expressing cells of patients with liver fibrosis
The PROM1 mRNA levels in 40 cirrhotic and 6 healthy livers from a human GEO database (GEO accession code GSE25097) were analyzed. Compared to those in the healthy livers, the mRNA levels of both PROM1 and fibrogenic genes such as those encoding αsmooth muscle actin (ACTA2), α1 type 1 collagen (COL1A1), and transforming growth factor β1 (TGFB1) were upregulated in the fibrotic liver, while mRNA level of TGFBR1 was not ( Fig. 1A) . The PROM1 mRNA levels were increased in proportion to those of ACTA2, COLA1, and TGFB1 in fibrotic livers ( Fig. 1B) , indicating that the PROM1 expression level is positively correlated with the progression of liver fibrosis. Next, we determined which cells express PROM1 in livers with mild and severe fibrosis by double immunofluorescence staining for cytokeratin-19 (CK19 for cholangiocytes and HPCs) and α-smooth muscle actin (αSMA for HSCs). PROM1 was mainly found in CK19-expressing cells but not in αSMAexpressing cells (Fig. 1C ), indicating that PROM1 is expressed in the cholangiocytes and HPCs of the human fibrotic liver. PROM1 was also clearly observed in hepatocyte plasma membrane (Fig. 1C ).
To further confirm the Prom1 upregulation in liver fibrosis, we induced liver fibrosis in mice by BDL and then assessed the liver Prom1 mRNA levels. In the BDL-treated liver, the Prom1 mRNA levels were increased in proportion to those of the fibrogenic markers Acta2, Col1a1, and Tgfb1 but not to the mRNA level of Tgfbr1 ( Fig. 2A ). We also determined the tissue distribution of PROM1 by double immunofluorescence staining for CK19 and αSMA in the liver. Prom1 was found in the livers of both sham and BDL mice in all CK19-expressing cells but not in αSMA-expressing cells (Fig. 2B ). The livers of BDL mice had substantially more PROM1-and CK19-expressing cells than those of the sham mice ( Fig. 2B ). These results indicate that Prom1 upregulation in the liver of BDL mice results from the expansion of CK19-and PROM1-expressing HPCs and cholangiocytes.
Prom1 was also found in the plasma membrane of hepatocytes, while its expression in the BDL mouse liver was not altered (Fig. 2B ).
In CCl 4 -treated mice, Prom1 mRNA levels were also increased in proportion to the mRNA levels of Acta2, Col1a1, Tgfb1 but not to the mRNA level of Tgfbr1 (Fig. 2C ).
Double immunofluorescence analysis showed that PROM1 was expressed in CK19expressing cells but not in αSMA-expressing cells ( Fig. 2D ). Prom1 was also clearly expressed in the hepatocyte plasma membrane of both control and CCl 4 -treated mice ( Fig.   2D ).
PROM1 deficiency aggravates BDL-and CCl 4 -induced liver fibrosis in mice
To understand the physiological function of PROM1 in the development of liver fibrosis, we induced liver fibrosis in Prom1 +/+ (WT) and Prom1 -/-(KO) mice by BDL or CCl 4 treatment. Prom1-expressing cells were found in only the Prom1 +/+ livers and their numbers were increased after BDL and CCl 4 treatment, indicating that the immunofluorescence signal was specific for PROM1. Hematoxylin and eosin (H&E) staining showed that the Prom1 -/liver had more nuclei around the central vein than the Prom1 +/+ liver after BDL or CCl 4 treatment ( Supplementary Fig. 1A ). Masson's trichrome, Sirius Red and αSMA immunostaining showed that BDL-or CCl 4 -induced collagen deposition and myofibroblast differentiation in the liver were increased by Prom1 deficiency (Fig. 3A) . However, the number of CK19-expressing cells was significantly increased in Prom1 -/mice compared to that in Prom1 +/+ mice in the BDL model but not in CCl 4 -treated mice (Fig. 3A) .
To determine BDL-or CCl 4 -induced liver fibrosis in Prom1 +/+ and Prom1 -/mice, we further analyzed the mRNA levels of genes associated with liver fibrosis. In BDL mice, Prom1 deficiency further increased the mRNA levels of TGFβ target genes (Col1a1, Acta2, Ctgf, Pai1 and Timp1), ductular reaction-related genes (Krt19), and cytokine genes (Il1b, Il6, Tnfa, and Ccl2) ( Fig. 3B and Supplementary Fig. 1B ). However, in CCl 4 -treated mice, although Prom1 deficiency further increased the mRNA levels of TGFβ target genes (Col1a1, Acta2, and Timp1), it did not change the mRNA levels of ductular reaction-related genes (Krt19), and cytokine genes (Il1b, Il6, Tnfa, and Ccl2).
Moreover, the blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin increased by BDL or CCl 4 treatment were further increased by PROM1 deficiency (Fig. 3C ), suggesting that PROM1 deficiency aggravates BDL-or CCl 4 -induced liver fibrosis.
PROM1 deficiency enhances TGFβ1 signaling in hepatocytes
Because Prom1 deficiency did not change the mRNA levels of Tgfb1 and Tgfbr1 in either BDL or CCl 4 -treated mice, we speculated that Prom1 may regulate TGFβ downstream signal transduction ( Fig. 3B ). Thus, we first examined TGFβ signaling in the liver after BDL and CCl 4 treatment. Immunostaining and immunoblotting for phospho-SMAD2/3 (p-SMAD2/3) showed that the BDL-and CCl 4 -induced phosphorylation of SMAD2/3 was increased to a greater extent in the Prom1 -/liver, than in the Prom1 +/+ liver ( Fig. 4A and B ).
Interestingly, Prom1 deficiency prevented the BDL-and CCl 4 -induced increase in SMAD7 protein expression without changing the mRNA level of Smad7 (Fig. 4B and C and Supplementary Fig. 2A ).
Because PROM1 was expressed in hepatocytes and Prom1 deficiency aggravated CCl 4 -induced liver fibrosis in which hepatocytes were mainly damaged, we examined the effect of PROM1 on TGFβ signaling in primary hepatocytes isolated from Prom1 +/+ and Prom1 -/mice. Prom1 deficiency further increased the TGFβ-induced phosphorylation of SMAD2/3 and TGFβ-induced Vimentin ( Fig. 5A and B ). The mRNA levels of TGFβ target genes (Snail1, Vimentin, Zeb1, and Zeb2) were also increased in TGFβ-exposed primary hepatocytes by Prom1 deficiency (Fig. 5C ). Interestingly, SMAD7 expression was higher in Prom1 +/+ hepatocytes than in Prom1 -/hepatocytes ( Fig. 5A and B ). Because the mRNA levels of Smad7 were not decreased in the liver or primary hepatocytes of Prom1 -/mice (Supplementary Fig. 2A and 3B ), SMAD7 might be posttranslationally stabilized in the presence of PROM1. Next, we examined TGFβ signaling after the adenoviral overexpression of PROM1 in Prom1 -/primary hepatocytes. Immunofluorescence and immunoblot analyses showed that PROM1 restoration prevented the TGFβ-induced phosphorylation of SMAD2/3 expression by increasing SMAD7 protein expression ( Fig. 5D and E).
PROM1 stabilizes the SMAD7 protein
To elucidate how PROM1 stabilizes SMAD7, we examined the molecular interaction between PROM1 and SMAD7. A reciprocal endogenous immunoprecipitation assay in the BDL-treated Prom1 +/+ liver showed a molecular interaction between PROM1 and SMAD7 ( Fig. 6A ). The interaction of PROM1 with SMAD7 was further demonstrated by exogenous immunoprecipitations in HEK 293T cells overexpressing both PROM1 and SMAD7 ( Fig.   6B ). To identify the domains of each protein that are necessary for the interaction, various truncation mutants of both PROM1 and SMAD7 were prepared ( Supplementary Fig. 4A and   B ). Co-immunoprecipitations of both PROM1 and SMAD7 mutants showed that the 1 st intracellular domain (IC1) of PROM1 interacted with the N-terminal (N) domain or Mad homology 2 (MH2) domain of SMAD7 because all PROM1 mutants with the IC1 domain interacted with all SMAD7 mutants ( Fig. 6C and D). To determine whether Prom1 stabilizes SMAD7, we overexpressed different combinations of PROM1, SMAD7 and SMURF1 and SMURF2 in HEK 293T cells and monitored SMAD7 protein expression by immunoblotting.
The SMAD7 protein levels were decreased by SMURF2 but restored by Prom1 in a dosedependent manner ( Fig. 6E and F ). In addition, SMAD7 ubiquitination which was induced by SMURF2 was abolished by PROM1 ( Fig. 6G ). The half-life of SMAD7 was determined by treating cells with cycloheximide (CHX). The half-life of SMAD7 in the presence of SMURF2 was increased 2-fold by PROM1 ( Fig. 6H ). To understand how PROM1 increases SMAD7 stability, we examined whether PROM1 and SMURF2 compete for interaction with SMAD7. Co-immunoprecipitation experiments showed that the molecular interaction between SMAD7 and SMURF2 was disrupted by PROM1 in a dose-dependent manner ( Fig.   6I ). Together, these data indicate that PROM1 abolishes SMURF2-induced SMAD7 ubiquitination by interfering with the molecular interaction between SMAD7 and SMURF2.
Liver-specific Prom1 deficiency aggravated BDL-induced liver fibrosis with reduced levels of SMAD7
To elucidate the specificity of hepatocytic PROM1 in liver fibrosis, we generated liver-specific Prom1 deficient mice (f/f : Alb-Cre) by crossing Prom1 f/f mice (f/f), containing two loxP sequence flanking exon 2 of Prom1 with Alb-Cre transgenic mice (Alb-Cre) ( Supplementary Fig. 5A ). PCR-based genotype of each mice were determined from the tail- Supplementary Fig. 5B and C). Liver-specific Prom1 deficiency was confirmed using primary hepatocytes, liver and kidney of Prom1 f/f :Alb-Cre mice and its littermate Prom1 f/f mice by immunoblotting ( Supplementary Fig. 5D ).
Next we analyzed BDL-induced liver fibrosis in Prom1 f/f and Prom1 f/f : Alb-Cre mice.
H&E, Sirius red and Masson's trichrome staining assays revealed that Prom1 f/f : Alb-Cre mice aggravated BDL-induced liver fibrosis compared to Prom1 f/f mice ( Supplementary Fig. 5E ).
BDL-induced expression of α SMA and CK19 was more increased in Prom1 f/f : Alb-Cre mice than in control Prom1 f/f mice as determined by qRT-PCR, immunofluorescence and immunoblotting, indicating that liver-specific Prom1 deficiency aggravated BDL-induced liver fibrosis ( Fig. 7A-C ). Immunofluorescence and immunoblotting shows that BDLinduced phosphorylation of SMAD2/3 was also more increased with reduced levels of Smad7 caused by liver-specific Prom1 deficiency ( Fig. 7A and B and Supplementary Fig. 5E and 5G). However, increase of Smad7 mRNA level after BDL did not differ, regardless of liverspecific knockout of Prom1 ( Supplementary Fig. 5F ). With all these data, we conclude that hepatocytic PROM1 plays a central role in the regulation of TGFβ signaling and liver fibrosis via SMAD7 stabilization.
Discussion
PROM1 was highly expressed in the fibrotic livers of human patients and mice ( Fig.   1 and 2 PROM1 is an important surface marker of normal and cancer stem cells and has several binding partners such as Actin, Radixin, PI3K, and HDAC6 28-31 . In addition to these binding partners, we demonstrated that PROM1 plays a central role in TGFβ signaling and liver fibrosis by stabilizing SMAD7 using both global and liver-specific Prom1 knockout mice. We believe that our study will shed light on a novel physiological function of PROM1 in liver fibrosis. In addition to the liver, fibrosis progresses in other organs such as the heart, lung, kidney, and skin where PROM1 is highly expressed 17, 32, 33 . Because the role of SMAD7 during fibrosis progression has been extensively studied in these organs 34-37 , a PROM1-SMAD7 axis will provide a better insight into understanding fibrosis in other organs. Each liver specimen was analyzed by PROM1 immunofluorescence, Masson's Trichrome staining, Sirius Red staining and H&E staining (E). The mRNA levels of Smad7 were determined by qRT-PCR and normalized to those of 18S rRNA (F). The expression levels of pSMAD2/3 and SMAD7 were normalized to that of GAPDH and statistically assessed (G).
Figure Legends
N=1 for sham group and N=3 for BDL group. *p < 0.05, **p < 0.01. Supplementary Table 1 . List of antibodies used in this study. Supplementary Table 2 . List PCR primers used in this study. 
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